NUTRACOB: NUTritional Impact of a Hypocaloric Hyperprotein Diet Before Obesity Surgery
Study Details
Study Description
Brief Summary
Obesity is a major public health problem and is constantly on the rise. Therapeutic approaches based on dietary advice, physical activity and the management of psychological difficulties are not always sufficient to achieve a lasting weight reduction.
Bariatric surgery (or obesity surgery), accompanied by therapeutic education and adequate medical and dietary monitoring, can lead to significant and lasting weight loss. It is indicated as a second-line treatment for patients who have failed medical treatment, whose BMI is greater than or equal to 40 or whose BMI is greater than or equal to 35 with comorbidities (type 2 diabetes, arterial hypertension, obstructive sleep apnoea-hypopnoea syndrome, severe joint disorders).
The surgeon may be very bothered by the intra-abdominal fat mass and especially by steatotic hepatomegaly (increase in the size of the liver and its fat load).
Faced with this problem, various preoperative strategies such as the placement of an intra gastric balloon have been tried to decrease the size of the liver but a systematic review from 2016 indicates that a low calorie diet is preferable. Preoperative weight loss can reduce fat load and liver volume very rapidly. This meta-analysis shows that all low-calorie, high-protein diets are effective and that the optimal duration (4 weeks), compliance and tolerance are important factors for success.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Obesity is a major public health problem and is constantly on the rise. Therapeutic approaches based on dietary advice, physical activity and the management of psychological difficulties are not always sufficient to achieve a lasting weight reduction.
Bariatric surgery (or obesity surgery), accompanied by therapeutic education and adequate medical and dietary monitoring, can lead to significant and lasting weight loss. It is indicated as a second-line treatment for patients who have failed medical treatment, whose BMI is greater than or equal to 40 or whose BMI is greater than or equal to 35 with comorbidities (type 2 diabetes, arterial hypertension, obstructive sleep apnoea-hypopnoea syndrome, severe joint disorders).
The surgeon may be very bothered by the intra-abdominal fat mass and especially by steatotic hepatomegaly (increase in the size of the liver and its fat load).
Faced with this problem, various preoperative strategies such as the placement of an intra gastric balloon have been tried to decrease the size of the liver but a systematic review from 2016 indicates that a low calorie diet is preferable. Preoperative weight loss can reduce fat load and liver volume very rapidly. This meta-analysis shows that all low-calorie, high-protein diets are effective and that the optimal duration (4 weeks), compliance and tolerance are important factors for success.
However, there is no consensus on the benefit/risk balance of a preoperative diet and there is considerable variability in approach at national and international level.
The present clinical study involves a triad of dietician, surgeon, physician (endocrinologist/nutritionist or internist) to secure this diet. It could provide a database to help estimate the risk of undernutrition in the obese subject.
This diet, designed to facilitate the surgical procedure and potentially reduce intraoperative complications, is inexpensive, easily accessible and reproducible by other teams. This innovative management could standardise the preoperative management of patients undergoing bariatric surgery at national level. It would also improve the results of bariatric surgery both in the short term by reducing complications and in the long term by increasing weight reduction as reported in the Livhits meta-analysis. The risk of undernutrition should be reduced by this hypocaloric hyperprotein diet and consequently cancel out the increased risk of mortality, infections, delayed healing, longer hospital stay and the costs that this would entail.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: With diet A low-calorie, high-protein diet will be prescribed to the patient for a period of 4 weeks. The diet will be done the 4 weeks before the bariatric surgery |
Dietary Supplement: With low-calorie, high-protein diet
A low-calorie, high-protein diet will be prescribed to the patient for a period of 4 weeks. The diet will be done the 4 weeks before the bariatric surgery
|
| Other: Without diet A low-calorie, high-protein diet will not be prescribed to the patient for a period of 4 weeks. |
Dietary Supplement: Without low-calorie, high-protein diet
A low-calorie, high-protein diet will not be prescribed to the patient for a period of 4 weeks.
|
Outcome Measures
Primary Outcome Measures
- Poor diet tolerance [4 weeks after the beggining of the diet]
At least one of the following biological abnormalities at the end of the diet period: Lymphopenia acquired during the diet Anemia (Hb<11g/dL for men Hb<10g/dL for women) or a decrease in hemoglobin of more than 2 g/dL Onset or worsening of vitamin B1 deficiency from baseline (Vit B1 < 78 nmol/L) OR At least one of the following clinical abnormalities: Decrease in muscle strength (difference in muscle strength measured with a HandGrip at Visit 2 and Visit 3) greater than three standard deviations from the matched Visit 3 - visit 2 differences of the control group after removal of measurement bias on a log-transformed strength variable, associated with weight loss > 5% in 1 month or a decrease in percent lean mass ≥ 1% relative to visit 2 Any permanent discontinuation
Secondary Outcome Measures
- Weight loss [4 weeks after the beggining of the diet and 3 months postoperatively]
Weight difference between Visit 3 and Visit 2
- Reduced muscle strength [4 weeks after the beggining of the diet]
Difference in muscle strength measured with a HandGrip at Visit 2 and Visit 3)
- Comparison of the quality of life between "with diet" and "without diet" with "EQVOD" questionnaire [Baseline, 4 weeks after the beggining of the diet and 3 months postoperatively]
Evaluated using the EQVOD questionnaire at baseline (V2), end of diet (V3) and 3 months postoperatively Score from 36 to 180
- Evolution of physical activity [Baseline, 4 weeks after the beggining of the diet and 3 months postoperatively]
Physical activity evaluated using the Ricci et Gagnon questionnaire at baseline (V2), end of diet (V3) and 3 months postoperatively
- Digestive tolerance [during the 4 weeks of the diet]
Digestive tolerance evaluated using auto-questionnaire about nausea, vomiting, diarrhoea, constipation forthe interventional group, in the month of the diet
- Compliance [during the 4 weeks of the diet]
Evaluated by a food diary and the full bottles (not consumed) brought back for the intervention group, in the month of the diet
- Degree of exposure [one day from surgery]
Assessment of the degree of exposure of the oesogastric junction and hepatomegaly on a subjective scale of 1 to 5 by the surgeon
- Operating time [one day from surgery]
Number of hours and minuts about surgery
- Length of hospital stay [Four months from surgery]
Number of days in hospital for the surgery
- Intraoperative and postoperative complications [Between surgery and 3 months postoperatively]
Delayed healing, infection and cancellation of surgery or conversion to laparotomy) up to 3 months post-operatively
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patient eligible for bariatric surgery (according to HAS criteria) whose sleeve gastrectomy is scheduled
-
Patient with morbid obesity (BMI ≥ 40)
-
Age ≥ 18 years and ≤ 65 years
-
Haemoglobinemia ≥ 12 g/dL in men and ≥ 11 g/dL in women
-
Patient speaking and understanding French
-
Adult having read and understood the information letter and signed the consent form
-
Woman of childbearing age with effective / very effective contraception (Cf. CTFG) (estrogen-progestin or intrauterine device or tubal ligation) prior to surgery and a negative -HCG blood pregnancy test at inclusion, for the duration of the study
-
Postmenopausal woman: confirmatory diagnosis (non-medically induced amenorrhoea for at least 12 months prior to the inclusion visit)
-
Patient affiliated with, or beneficiary of a social security (health insurance) category
Exclusion Criteria:
-
Contraindication to bariatric surgery detected during the preoperative assessment
-
Medical contraindication to a restrictive diet
-
Type I or II insulin-requiring diabetes
-
Severe renal insufficiency defined by a blood filtration rate < 30 mL/min
-
Person wearing a pacemaker or any other implant with the same functions (cochlear implant, bladder battery, etc.)
-
Person deprived of liberty by an administrative or judicial decision or person placed under judicial protection / sub-guardianship or curatorship
-
A history of illness or psychological or sensory abnormality likely to prevent the subject from fully understanding the conditions required for participation in the protocol or to prevent him/her from giving informed consent
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- University Hospital, Rouen
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2019/414/HP